Clinical Trial Detail

NCT ID NCT04330664
Title Phase 1/2 Study of MRTX849 Plus TNO155 in Patients With Cancer Having a KRAS G12C Mutation
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications

lung non-small cell carcinoma

Advanced Solid Tumor

colorectal cancer

Therapies

MRTX849 + TNO155

Age Groups: adult senior

No variant requirements are available.